LYPQOZET (atorvastatin calcium; ezetimibe) by Merck & Co. is 12. Approved for elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b) and 8 more indications. First approved in 2017.
Drug data last refreshed 1w ago
12.1 Mechanism of Action LYPQOZET Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. LYPQOZET contains ezetimibe and atorvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the…
Worked on LYPQOZET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.